

# Faisal Saeed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9626603/publications.pdf>

Version: 2024-02-01

16  
papers

673  
citations

858243

12  
h-index

1113639

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1416  
citing authors

#	ARTICLE	IF	CITATIONS
1	Skene gland adenocarcinoma: Clinicopathologic features, comprehensive biomarker analysis, and review of the literature. <i>Pathology International</i> , 2021, 71, 712-714.	0.6	5
2	[ <sup>18</sup> F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 734-740.	0.2	16
3	Primary effusion lymphoma of the pleural space: Report of a rare complication of cardiac transplant with review of the literature. <i>Transplant Infectious Disease</i> , 2019, 21, e13005.	0.7	9
4	166 A Case of Atypical Lymphoproliferative Disorder of NK Cells: An Aggressive Immunophenotype but Indolent Behavior With Normal Cytogenetics. <i>American Journal of Clinical Pathology</i> , 2018, 149, S70-S71.	0.4	0
5	A rare case of metastatic sarcomatoid variant of urothelial carcinoma arising after failed renal allograft. <i>Human Pathology: Case Reports</i> , 2017, 8, 31-34.	0.2	0
6	Identification of a Novel 1,2,3,4-Tetrahydrobenzo[ <i>b</i> ][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8858-8875.	2.9	47
7	PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 295-302.	1.2	40
8	Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 707-721.	1.2	24
9	Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38 $\beta$ MAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models. <i>ACS Chemical Neuroscience</i> , 2015, 6, 666-680.	1.7	75
10	Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease. <i>Scientific Reports</i> , 2014, 4, 7190.	1.6	84
11	Dynamin 1 Is Required for Memory Formation. <i>PLoS ONE</i> , 2014, 9, e91954.	1.1	32
12	Alzheimer's Therapeutics Targeting Amyloid Beta 1-42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits. <i>PLoS ONE</i> , 2014, 9, e111898.	1.1	120
13	Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2013, 60, 285-294.	2.6	96
14	Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. <i>PLoS ONE</i> , 2013, 8, e66226.	1.1	58
15	5-HT <sub>4</sub> Receptor Stimulation Leads to Soluble A $\beta$ Production Through MMP-9 Upregulation. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 437-445.	1.2	18
16	Preparation of Oligomeric $\beta$ -amyloid <sub>1-42</sub> and Induction of Synaptic Plasticity Impairment on Hippocampal Slices. <i>Journal of Visualized Experiments</i> , 2010, , .	0.2	45